Get the Stockscreener App
3.91
5.96%
0.22
Pre-market:
3.92
0.010
+0.26%
Bioatla Inc stock is traded at $3.91, with a volume of 28,514.
It is up +5.96% in the last 24 hours and down -19.71% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
See More
Previous Close:
$3.69
Open:
$3.76
24h Volume:
28,514
Relative Volume:
0.77
Market Cap:
$6.48M
Revenue:
$2.00M
Net Income/Loss:
$-59.61M
P/E Ratio:
-0.1033
EPS:
-37.8642
Net Cash Flow:
$-48.20M
1W Performance:
+1.03%
1M Performance:
-19.71%
6M Performance:
-90.81%
1Y Performance:
-79.95%
1-Day Range:
$3.61
$4.15
1-Week Range:
$3.37
$4.15
52-Week Range:
$3.26
$71.50
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
3.91 | 6.11M | 2.00M | -59.61M | -48.20M | -37.86 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
BCAB Technical Analysis | Trend, Signals & Chart Patterns | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BioAtla (BCAB) Q4 2025 Earnings: EPS $-8.00 Beats EstimatesStrong Earnings Momentum - The Legal Advocate
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Sahm
BCAB Stock Price, Quote & Chart | BIOATLA INC (NASDAQ:BCAB) - ChartMill
Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal - Moomoo
Context Therapeutics Secures Full Rights to CT-202 from BioAtla with License Buyout, Phase 1 Trial Planned for Q3 2026 - Minichart
Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free - TradingView
Context Therapeutics enters into license agreement amendment with BioAtla for CT-202 - marketscreener.com
Context Therapeutics (CNTX) secures fully paid-up, non-terminable CT-202 license - Stock Titan
Context to pay $6.5M for full CT-202 rights by Aug. 1, 2026 - Stock Titan
The real story behind BioAtla BCAB valuation 333 20260507Community Sell Signals - Newser
BioAtla (BCAB) slashes R&D, flags going-concern risk amid cash crunch - Stock Titan
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Number of shareholders of BioAtla, Inc. – NASDAQ:BCAB - TradingView
BioAtla (BCAB) Stock Analysis: +2.61% Gain — What to Watch 2026-05-14Continuation Pattern - newser.com
BCAB Q1'26 Earnings: EPS estimate is (10.00) USD - TradingView
TradingKey - TradingKey
The real story behind BioAtla (BCAB) valuation (-3.33%) 2026-05-07Quote Data - Newser
BCAB BioAtla delivers narrower than expected Q4 2025 loss, shares gain nearly two percent today.Social Trade Signals - newser.com
Why is BioAtla (BCAB) stock gaining attention recently | Q4 2025: Better Than ExpectedMarket Hype Signals - Newser
BioAtla, Inc. Executive Compensation, Governance, and Board Diversity Overview 2025 - Minichart
Executive pay, board and share data detailed in BioAtla (NASDAQ: BCAB) 10-K/A - Stock Titan
Is BioAtla (BCAB) stock reacting to key levels | Q4 2025: Earnings Beat EstimatesQuarterly Financial Update - Newser
BioAtla to implement 50-for-1 share consolidation - MSN
BCAB Stock Chart | BIOATLA INC (NASDAQ:BCAB) - ChartMill
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Highs Report: What is the dividend yield of BioAtla IncPortfolio Performance Report & Verified Technical Signals - baoquankhu1.vn
BCAB Q4 2025 Earnings: BioAtla Inc. EPS Beats Estimates With No Revenue - Newser
BCAB Stock Analysis: BioAtla Inc. Biotech Drops 3.12% to $0.13 Key Takeaways - Newser
BioAtla Announces 1-for-50 Reverse Stock Split Merger - TipRanks
[8-K] BioAtla, Inc. Reports Material Event - Stock Titan
Bio files certificate of merger; 50-for-1 reverse stock split effective Apr 6 - TradingView
12 Health Care Stocks Moving In Wednesday's Intraday Session - Sahm
BioAtla To Carry Out 1-for-50 Reverse Stock Split On April 6th, 2026 - Moomoo
BCAB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
BioAtla announces 50-for-1 reverse stock split effective April 6 - Investing.com Australia
BioAtla announces 50-for-1 reverse stock split effective April 6 By Investing.com - Investing.com South Africa
BioAtla Begins Strategic Review Following 2025 Results - TipRanks
BioAtla Announces 50-for-1 Share Consolidation - National Today
BioAtla Announces Share Consolidation - Investing News Network
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
BioAtla Q4 net loss narrows on lower expenses - TradingView
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - The Manila Times
BRIEF-BioAtla Q4 Net Income USD -9.784 Million - TradingView
Strategic shake-up at BioAtla (NASDAQ: BCAB) as oncology pipeline and funding plans are reassessed - Stock Titan
BioAtla (NASDAQ: BCAB) posts 2025 loss, launches asset monetization review - Stock Titan
Aug Decliners: How much upside does BioAtla Inc haveCPI Data & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
BioAtla, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aug Wrap: Will BioAtla Inc stock hit new highs in YEAR2026 Bull vs Bear & AI Based Trade Execution Alerts - baoquankhu1.vn
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):